Summary of Purpose
The overarching objective of the Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART) trial is to assess whether a polypill containing fixed doses of (2/3) antihypertensives, a statin and antiplatelet therapy taken once daily orally would result in carotid intimal thickness regression-a surrogate marker of atherosclerosis, improved adherence, and tolerability compared...Read More →
The following dates are available for this trial. Trial information last updated on 11 January 2018.
|1 Mar 2018||28 Aug 2017||1 Aug 2018||1 Aug 2019||1 Jan 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|